AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced it will present new data in genitourinary malignancies at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), taking place February 26-28, 2026. Across four oral presentations in muscle-invasive bladder cancer (MIBC), these data reinforce Signatera's role in identifying patients who benefit from adjuvant immunotherapy, supporting. ...

should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are ...

Telix Pharmaceuticals (NasdaqGS:TLX) FY Conference February 26, 2026 04:40 PM ET Company ParticipantsChristian Behrenbruch - Managing Director and Group Chief Executive OfficerConference Call ParticipantsJeff Jones - Managing Director and Senior Analyst, BiotechnologyJeff JonesGood afternoon, everyone. Welcome back to the afternoon session of Oppenheimer's Annual Healthcare Conference. I'm Jeff Jones, one of the analysts on the biotech team here. I am delighted to be joined by Christian Behrenbruch, CEO of ...

Caris Life Sciences (NasdaqGS:CAI) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsBobby Hill - CCOBrian Brille - Vice Chairman and EVPColleen Babington - Equity Research AssociateDavid Spetzler - PresidentLuke Power - CFOMichael Ryskin - Managing DirectorPatrick Donnelly - Managing Director, Equity ResearchRuss Denton - General CounselSubbu Nambi - Managing Director and Healthcare Equity ResearchVijay Kumar - Senior Managing DirectorConference Call ParticipantsDaniel Brennan - Senio ...

Caris Life Sciences (NasdaqGS:CAI) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsBobby Hill - CCOBrian Brille - Vice Chairman and EVPColleen Babington - Equity Research AssociateDavid Spetzler - PresidentLuke Power - CFOMichael Ryskin - Managing DirectorPatrick Donnelly - Managing Director, Equity ResearchRuss Denton - General CounselSubbu Nambi - Managing Director and Healthcare Equity ResearchVijay Kumar - Senior Managing DirectorConference Call ParticipantsDaniel Brennan - Senio ...

Caris Life Sciences (NasdaqGS:CAI) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Speaker9Everyone, and welcome to the Caris Life Sciences Q4 2025 earnings call. My name is Dana, and I will be your coordinator today. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising that your han ...

Q4 2025 Earnings Call February 26, 2026 Important Information and Disclaimer Where Molecular Science Meets Artificial Intelligence Forward-Looking Statements This presentation contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this presentation are forward-looking statements, including statements regarding our business, solutions, plans, object ...

Core Insights - Caris Life Sciences reported a significant revenue growth of 97% for the full year 2025, driven by strong performance in molecular profiling services [1] - The company expects full year 2026 revenue to be in the range of $1.0 billion to $1.02 billion, indicating a growth of approximately 23% to 26% compared to 2025 [1] Financial Highlights - Fourth Quarter 2025 total revenue was $292.9 million, a 125% increase from $129.9 million in Q4 2024, primarily due to a 199% growth in molecular profiling services revenue [1][3] - Full Year 2025 total revenue reached $812.0 million, up from $412.3 million in 2024, with molecular profiling services revenue growing by 120% to $766.7 million [1][3] - Gross margin improved to 75% in Q4 2025 from 54% in Q4 2024, and for the full year, it was 66%, up from 43% in 2024 [1][3] Operating Performance - The company completed approximately 52,700 clinical therapy selection cases in Q4 2025, a 20% increase year-over-year, and around 199,300 cases for the full year, a 22% increase [1] - Positive net cash provided by operating activities was $44.8 million in Q4 2025, compared to a net cash used of $38.9 million in Q4 2024, marking a 215% improvement [1][3] Future Outlook - Caris anticipates clinical therapy selection volume to grow approximately 20% in 2026 compared to 2025 [1] - The company announced a collaboration with Genentech to discover novel therapeutic targets in cancers with high unmet clinical need [1]

Initial Phase 1 data of zovegalisib in PIK3CA-driven vascular anomalies expected to be announced in first half of 2026 Breast cancer triplet data and frontline Phase 3 plans expected to be announced in 2026 Initial Phase 1/2 data of zovegalisib + fulvestrant at 400mg BID fed (Phase 3 dose) in CDK4/6-experienced patients to be presented at ESMO TAT on March 16, 2026 Approximately $555 million in cash, cash equivalents and investments at end of Q4 2025 CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Rela ...

Key Takeaways TEM reported 83% Q4 revenue growth, fueled by Diagnostics and Data segment strength. Tempus AI achieved positive adjusted EBITDA, though GAAP loss hit $54.2M on stock comp and charges. Illumina posted 5% revenue growth and margin gains, despite tariff-driven gross margin pressure. In 2026, MedTech players' success will hinge on their ability to balance near-term pressure with long-term transformation. Per a report by ZS, these players must address immediate operational, financial, and regulato ...